Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | IR plus R-HCVAD/R-MTX efficacious for young MCL in the first-line

A study of ibrutinib-rituximab plus short course R-HCVAD/R-MTX for previously untreated, young mantle cell lymphoma (MCL) patients was presented by M. Wang at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. Here, his colleague Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, discusses the findings.